

<b>Notice of References Cited</b>	Application/Control No. 10/530,567	Applicant(s)/Patent Under Reexamination BARGE, ALAN	
	Examiner Meghan Finn	Art Unit 1614	Page 1 of 1

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2003/0096875 A1	05-2003	Burton et al.	514/703
*	B	US-6,953,679	10-2005	Salvati et al.	435/121
*	C	US-2002/0002162	01-2002	Lee, Francis Y.	514/221
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Bruns et al., Effect of the Vascular Endothelial Growth Factor Receptor-2 Antibody DC101 Plus Gemcitabine on Growth Metastasis and Angiogenesis of Human Pancreatic Cancer Growing Orthotopically in Nude Mice, 2002, Int. J. Cancer, vol. 102, pages 101-108.
	V	Sepp-Lorenzino et al., Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development, 2002, Expert Opin. Investig. Drugs, vol 11, issue 10, pages 1447-1465.
	W	Ostruszka et al., The Role of Cell Cycle Progression in Radiosensitization by 2',2'-Difluoro-2'-deoxycytidine, 2000, Cancer Research, vol 60, pages 6080-6088.
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.